98482-69-0

Upstream product

• 5545-52-8 Z-D(tBu)-OH 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 41446-22-4 (S)-3-Benzyloxycarbonylamino-4-isobutoxycarbonyloxy-4-oxo-butyric acid tert-butyl ester 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 98482-70-3 (S)-4-oxo-3-{[(phenylmethoxy)carbonyl]amino}butanoic acid 1,1-dimethylethyl ester 
• 192755-43-4 3-[(9-benzoylamino-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carbonyl)-amino]-4-oxo-butyric acid tert-butyl ester 
• 234752-71-7 3-[(9-benzoylamino-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carbonyl)-amino]-N-methoxy-N-methyl-succinamic acid tert-butyl ester 
• 98482-71-4 (benzyloxycarbonyl)-β-tert-butyl-L-aspartyl-ψ(CH2-NH)-L-phenylalanine amide 
• 98482-73-6 (tert-butyloxycarbonyl)-L-leucyl-β-tert-butyl-L-aspartyl-ψ(CH2-NH)-L-phenylalanine amide 
• 98482-72-5 (S)-3-Amino-4-((S)-1-carbamoyl-2-phenyl-ethylamino)-butyric acid tert-butyl ester; hydrochloride 
• 142955-60-0 ((2S,3S)-2-{(S)-Hydroxy-[(S)-1-((S)-8-hydroxy-1-oxo-isochroman-3-yl)-3-methyl-butylcarbamoyl]-methyl}-5-oxo-tetrahydro-furan-3-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Total Synthesis of Originally Proposed and Revised Structure of Hetiamacin A

The first total synthesis of the originally proposed and correct structures of hetiamacin A has been accomplished via Wittig olefination and Sharpless asymmetric dihydroxylation reaction. These total syntheses culminated in the stereostructural confirmati

Total synthesis method of hetiamacin A

The invention relates to a total synthesis method of hetiamacin A. The method comprises the steps as follows: a compound (S)-3-((S)-1-amino-3-methylbutyl)-8-hydroxy 3,4-dibydro-isobenzopyran-1-ketone and a compound (2S,3S,4S)-2-amino-4-(carbobenzoxy amino

Isoxazoline derivative and a process for the preparation thereof

The present invention provides to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. The present invent

Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors

The present invention provides methods for expanding and increasing survival of hematopoietic cell populations, for prolonging viability of an organ for transplantation, and enhancing bioproduction, using interleukin-1β-converting enzyme (ICE)/CED-3 famil

Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors

The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1β-converting enzym

Methods, compositions and kits for preserving antigenicity

The present invention relates generally to programmed cell death and specifically to methods, compositions, and kits for preserving or enhancing antigenicity of markers associated with disease by utilizing inhibitors of apoptosis including interleukin-1β-

(Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases

This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of pa

Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors

The present invention provides methods for expanding and increasing survival of hematopoietic cell populations, for prolonging viability of an organ for transplantation, and enhancing bioproduction, using interleukin-1β-converting enzyme (ICE)/CED-3 famil

TREATMENT OF INFECTIOUS DISEASE USING INTERLEUKIN-1BETA-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS

The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1β-converting enzym

Structure-based design of nonpeptide inhibitors of interleukin-1β converting enzyme (ICE, Caspase-1)

A novel class of reversible inhibitors of Interleukin-1β-converting enzyme (ICE, caspase-1) were discovered by iterative structure-based design. Guided by the X-ray crystal structure of analogues 1, 7 and 10 bound to ICE, we have designed a non-peptide series of small molecule inhibitors. These compounds incorporate an arylsulfonamide moiety which replaces Val-His unit (P3-P2 residues) amino acids of the native substrate. The synthesis of the core structure, structure-activity relationships (SARs), and proposed binding orientation based on molecular modeling studies for this serie of ICE inhibitors are described. Copyright